Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Eupraxia Pharmaceuticals Inc. EPRXF OTC

Other OTC • Healthcare • Biotechnology • CA • USD

SharesGrow Score
15/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Eupraxia Pharmaceuticals Inc. (EPRXF) is a Biotechnology company in the Healthcare sector, currently trading at $3.04. It has a SharesGrow Score of 14/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $38M (loss), growing at -180%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $14M against $3M equity (Debt-to-Equity (D/E) ratio 4.72, leveraged). Current ratio is 1.02 (adequate). Debt-to-assets is 51.6%. Total assets: $27M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 17/100 (Fail), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

EPRXF SharesGrow Score Overview

20/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 17/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — EPRXF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
EPRXF: +0%/yr revenue is, -180%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
17/100
Balance sheet EPRXF: Debt-to-Equity (D/E) ratio 4.72 (leveraged), Current ratio is 1.02 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
EPRXF: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.9341-6.7764
Volume800
Avg Volume (30D)2.42K
Market Cap$108.29M
Beta (1Y)1.40
Share Statistics
EPS (TTM)-1.58
Shares Outstanding$24.15M
IPO Date2021-08-03
Employees21
CEOJames A. Helliwell FRCPC,
Financial Highlights & Ratios
Gross Profit$-209.91K
EBITDA$-37.68M
Net Income$-38.09M
Operating Income$-37.89M
Total Cash$25.5M
Total Debt$13.78M
Net Debt$-11.72M
Total Assets$26.72M
Price / Earnings (P/E)-1.9
Analyst Forecast
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD
ISINCA29842P1053

Price Chart

Track all markets on TradingView
EPRXF
Eupraxia Pharmaceuticals Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
2.93 52WK RANGE 6.78

People Also View

CELC
CELC
Celcuity Inc.
$120.85
+0.37%
 ELVN
ELVN
Enliven Therapeutics, Inc.
$44.85
+2.33%
 ASCLF
ASCLF
Ascletis Pharma Inc.
$2.10
+0.00%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.19
+7.40%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 MACK
MACK
Merrimack Pharmaceuticals, Inc.
$15.15
+0.10%
 FENC
FENC
Fennec Pharmaceuticals Inc.
$6.25
+5.40%
 TRGNF
TRGNF
Transgene SA
$1.00
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message